Shots :
- Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli (ranibizumab-eqrn) along with its supporting commercial infrastructure
- As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up-front payment along with an additional amount for Cimerli product inventory & subject to customary working capital adjustments at the closing date. The transaction is expected to close by H1’24
- Moreover, the divestiture also includes Coherus’ BLA for Cimerli, ophthalmology sales, select field reimbursement teams, Cimerli product inventory on hand & the access to proprietary commercial software
Ref: Coherus & Sandoz | Image: Coherus and Sandoz| Press Release
Related News:- Celltrion Reports BLA Submission for CT-P47 (Biosimilar, Actemra) to the US FDA for Treating Rheumatoid Arthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
